CD20×CD3 Bispecific Antibodies in Relapsed/Refractory B-Cell Lymphomas: Recent Phase III Evidence Durability, and Safety. (2026). Journal of Medical Sciences, 21(2), 30-35. https://doi.org/10.51984/szn7cg42